The role of fat and inflammation in the pathogenesis and management of osteoarthritis
Tirzepatide goes a step further as a dual agonist, activating both the GIP and GLP-1 receptors
GLP-1 medications carry an FDA warning for anyone with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (MEN) syndrome
This fragmented landscape leaves many Medicaid enrollees without timely access despite medical need, making out-of-pocket options like PlexusDx an increasingly practical solution
Large-scale human studies and regulatory reviews have not identified increased cancer risk, including breast cancer, with GLP-1 receptor agonists
Community-reported seasonal protocols commonly cycle (8 weeks on, 8 weeks off, per the melanotan-1 dosing guide), sometimes citing receptor desensitization as the rationale